![]() |
市場調査レポート
商品コード
1777243
医薬品用ゼラチンの世界市場:成長、将来展望、競合分析 (2025年~2033年)Pharmaceutical Gelatin Market - Growth, Future Prospects and Competitive Analysis, 2025 - 2033 |
||||||
|
医薬品用ゼラチンの世界市場:成長、将来展望、競合分析 (2025年~2033年) |
出版日: 2025年06月02日
発行: Acute Market Reports
ページ情報: 英文 188 Pages
納期: 即日から翌営業日
|
世界の医薬品用ゼラチン市場は、2024年から2033年にかけてCAGR 5.6%で成長しています。医薬品用ゼラチンはコラーゲン由来の精製タンパク質で、カプセル製造、創傷被覆材、血漿拡張剤、座薬、ワクチン安定剤などの用途に製薬業界全体で広く使用されています。熱可逆性、生体適合性、高いフィルム形成能力などのユニークな機能特性により、重要な賦形剤の役割を果たしています。カプセルベースのドラッグデリバリーに対する需要の増加は、放出制御型製剤の進歩と相まって、医薬品製造におけるゼラチンの消費を大幅に押し上げています。
さらに、世界の老人人口の増加により、ゼラチンがコーティングや充填材料として使用される栄養補助食品や医薬品の需要が増加していることも、市場の成長を後押ししています。さらに、消費者の嗜好がクリーンラベルで消化しやすい剤形にシフトしているため、ゼラチンは製剤メーカーに支持され続けています。近年、製薬会社はハラル、コーシャ、BSEフリーの供給源にも注目し始めており、ゼラチンの調達パターンに影響を与え、動物や魚由来の代替ゼラチン溶液の技術革新に拍車をかけています。
さらに、ソフトカプセルやハードカプセルの充填システムなどのカプセル化プロセスにおける技術的強化は、医薬品製造におけるゼラチン使用の拡張性と品質を向上させ、それによって市場の成長を支えています。医薬品グレードのゼラチンに対する規制上の支援と、特に腫瘍学と個別化医療におけるカプセルベースの治療薬への投資の増加は、先進地域と発展途上地域の両方で有利な機会を開くと予想されます。しかし、原材料の価格変動、家畜由来の原材料に関連するサプライチェーンリスク、非動物性代替品の人気の高まりによって市場の拡大は緩やかになり、医薬品製剤メーカーの今後の調達戦略に影響を与える可能性があります。
市場の分類と分析
種類別では、A型ゼラチンとB型ゼラチンに区分されます。2023年には、A型ゼラチンが、その迅速なゲル化特性、中性臭、ソフトカプセル製造における幅広い使用により、より大きな市場シェアを占めました。A型ゼラチンは主に豚原料から酸処理工程を経て製造されます。収率が高く、製薬用途に適した一貫した物理化学的特性を持つことから、このセグメントは優位性を維持すると予想されます。しかし、ウシ原料からアルカリ加水分解法で製造されるB型ゼラチンは、予測期間中に安定的に成長すると予測されます。ウシ由来のゼラチンに対する需要の増加は、特にブタの消費に食事上および宗教上の制限がある国々で顕著であり、ハラルおよびコーシャ認証の医薬品製剤への採用が強化されると予想されます。さらに、B型ゼラチンはブルーム強度が高く、保存可能期間が長いため、安定性の高い製剤に有利であることも需要を後押ししています。
地域別の市場分析
医薬品用ゼラチン市場は、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカの各地域で分析されています。欧州は2023年に医薬品用ゼラチンの世界市場を席巻し、最大の収益シェアを占めました。同地域の高度な医薬品製造能力、定評あるゼラチン供給業者、高品質の医薬品賦形剤を保証する厳格な規制基準などがその理由です。ドイツ、フランス、イタリアなどの国々は、カプセルと生ゼラチンの強力な国内生産に支えられ、主要な貢献者となっています。さらに、Gelita AG、Weishardt Group、Lapi Gelatineなどの世界のゼラチンメーカーの存在は、サプライチェーンにおける欧州の主導的地位を強化しています。
競合情勢
医薬品用ゼラチン市場は適度に断片化されており、世界プレーヤーと地域メーカーが混在しています。この領域で事業を展開している主要企業には、Funingpu Biotechnology、Gelita AG、India Gelatine &Chemicals、Junca Gelatines、Lapi Gelatine、Nitta Gelatin、Sterling Biotech、Trobas Gelatine、Weishardt Group、Xiamen Gelken Gelatinがあり、その他の主要企業も含まれます。2023年には、これらの企業は、垂直統合戦略、品質認証、製薬会社との長期供給契約を通じて、市場シェアの大半を占めています。
The global pharmaceutical gelatin market is growing at a CAGR of 5.6% from 2024 to 2033. Pharmaceutical gelatin, a purified protein derived from collagen, is extensively used across the pharmaceutical industry for applications such as capsule manufacturing, wound dressings, plasma expanders, suppositories, and vaccine stabilizers. It serves as a critical excipient due to its unique functional properties including thermo-reversibility, biocompatibility, and high film-forming capability. The increase in demand for capsule-based drug delivery, coupled with advancements in controlled-release drug formulations, is significantly boosting the consumption of gelatin in pharmaceutical production.
The growth of the market is further driven by a rising geriatric population globally, which in turn increases the demand for nutraceutical and pharmaceutical products where gelatin is used as a coating and filling material. Furthermore, as consumer preferences shift toward clean-label and easily digestible dosage forms, gelatin continues to be favored by formulators. In recent years, pharmaceutical companies have also begun focusing on halal, kosher, and BSE-free sources, influencing the sourcing patterns for gelatin and spurring innovation in alternative animal and fish-based gelatin solutions.
Moreover, technological enhancements in encapsulation processes, such as softgel and hard capsule filling systems, have improved the scalability and quality of gelatin usage in drug manufacturing, thereby supporting market growth. Regulatory support for pharmaceutical-grade gelatin and rising investment in capsule-based therapeutics, especially in oncology and personalized medicine, are expected to open lucrative opportunities in both developed and developing regions. However, market expansion is moderated by price fluctuations in raw materials, supply chain risks linked to livestock-derived sources, and the growing popularity of non-animal alternatives, which may influence future procurement strategies for pharmaceutical formulators.
Market Segmentation Analysis
By Type, the pharmaceutical gelatin market is segmented into Type A and Type B gelatin. In 2023, Type A gelatin accounted for a larger market share owing to its rapid gelling properties, neutral odor, and wide use in soft capsule production. It is predominantly produced using an acid treatment process from porcine raw material. The segment is expected to retain its dominance due to higher yield rates and consistent physicochemical properties suited for pharmaceutical applications. However, Type B gelatin, manufactured using alkaline hydrolysis from bovine sources, is projected to grow steadily over the forecast period. Increasing demand for bovine-derived gelatin, particularly in countries with dietary and religious restrictions on porcine consumption, is anticipated to reinforce its adoption in halal and kosher-certified drug formulations. Additionally, the demand for Type B gelatin is also being fueled by its higher bloom strength and extended shelf life, which is favorable in high-stability drug formulations.
By Source, the market is categorized into Porcine, Bovine, Fish, and Poultry. Porcine-derived gelatin remained the most widely used source in 2023 due to its superior quality, well-established processing infrastructure, and lower cost of production. It is extensively employed in soft and hard capsule manufacturing, especially in the North American and European pharmaceutical sectors. However, bovine gelatin is witnessing increased demand and is expected to grow at a notable pace through 2033 due to its religious acceptability in Muslim and Jewish populations. Moreover, food and pharmaceutical safety regulations are pushing companies to certify their products as BSE-free, prompting a shift toward more traceable and disease-free bovine sources. Fish gelatin is gaining attention as a viable alternative in regions with cultural or ethical concerns regarding land animal-derived products. Its popularity is particularly rising in marine collagen applications and among pescatarian consumers, although it still accounts for a smaller share of the market due to challenges in achieving consistent gelling strength and limited industrial-scale production. Poultry-based gelatin is a niche segment with emerging interest, mostly explored for biomedical and wound care applications, and may gain momentum in specialized pharmaceutical use cases.
Regional Market Analysis
Geographically, the pharmaceutical gelatin market is analyzed across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Europe dominated the global pharmaceutical gelatin market in 2023, accounting for the largest revenue share, attributed to the region's advanced pharmaceutical manufacturing capabilities, well-established gelatin suppliers, and strict regulatory standards ensuring high-quality pharmaceutical excipients. Countries such as Germany, France, and Italy are key contributors, supported by strong domestic production of both capsules and raw gelatin. Additionally, the presence of global gelatin manufacturers such as Gelita AG, Weishardt Group, and Lapi Gelatine reinforces Europe's leading position in the supply chain.
Asia-Pacific is expected to register the fastest growth during the forecast period, driven by increased pharmaceutical production outsourcing, rising healthcare expenditure, and growing demand for gelatin capsules in nutraceuticals and traditional medicine formulations. India and China are emerging as key manufacturing hubs, not only for generic pharmaceuticals but also for gelatin production, owing to favorable government incentives and abundant raw material availability. Moreover, rising consumer preference for dietary supplements, combined with growth in personalized therapies, is further augmenting gelatin consumption in the region.
North America held a significant market share in 2023, led by the United States due to high demand for advanced drug delivery systems, increasing elderly population, and strong pharmaceutical R&D activities. However, regulatory scrutiny over sourcing and animal-derived ingredients may influence sourcing dynamics in the future. Latin America and the Middle East & Africa are emerging regions with growing pharmaceutical infrastructure, but their contribution to the global market remains modest. Nevertheless, increasing investments in local manufacturing, especially in Brazil, Mexico, Saudi Arabia, and South Africa, indicate potential for future market expansion in these regions.
Competitive Landscape
The pharmaceutical gelatin market is moderately fragmented, with a mix of global players and regional producers. Key companies operating in the space include Funingpu Biotechnology, Gelita AG, India Gelatine & Chemicals, Junca Gelatines, Lapi Gelatine, Nitta Gelatin, Sterling Biotech, Trobas Gelatine, Weishardt Group, and Xiamen Gelken Gelatin, along with several Other Notable Players. In 2023, these players collectively accounted for the majority of the market share through vertical integration strategies, quality certifications, and long-term supply contracts with pharmaceutical companies.
Prominent players such as Gelita AG and Nitta Gelatin have emphasized innovation in specialty gelatin for pharmaceutical-grade applications and launched targeted offerings such as low-endotoxin gelatin for parenteral formulations. In Asia, companies like Funingpu and Xiamen Gelken are expanding capacity and upgrading production lines to meet global GMP standards, thus increasing their competitiveness in international markets. Companies are also actively investing in traceability, sustainability, and halal/kosher certifications to cater to evolving customer preferences and regulatory norms. Furthermore, strategic partnerships, acquisitions, and geographic expansions remain core strategies to tap into untapped regional markets and ensure uninterrupted raw material supply chains in the post-COVID landscape.
Historical & Forecast Period
This study report represents an analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.
The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Pharmaceutical Gelatin market are as follows:
Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users & consumption volume, price, and value.
Geographical revenues generated by countries considered in the report
Micro and macro environment factors that are currently influencing the Pharmaceutical Gelatin market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.